🇺🇸 FDA
Patent

US 8030307

Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease

granted A61KA61K38/00A61P

Quick answer

US patent 8030307 (Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease) held by Enanta Pharmaceuticals, Inc. expires Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Oct 04 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K38/00, A61P, A61P31/12